Apr 14, 2020
Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020
Apr 08, 2020
Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer
Mar 24, 2020
Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
Mar 18, 2020
Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti
Mar 08, 2020
Immutep Receives Second IND Approval for Efti from US FDA
Feb 18, 2020
Immutep Reports Positive TACTI-002 Data
Feb 04, 2020
Immutep to Present TACTI-002 Interim Data at German Cancer Congress
Jan 29, 2020
Immutep Activities Report
Jan 08, 2020
Immutep Expands Part C of TACTI-002 Due to Positive Data
Dec 18, 2019
INSIGHT-004 Clinical Trial Update
Nov 13, 2019
Immutep Announces European Patent Grant for LAG525 Antibody
Nov 07, 2019
Immutep Presents Positive Interim Data from Phase II TACTI-002 Trial at SITC
